PO.TB03.03 · 肿瘤生物学
在高级别浆液性卵巢癌基因工程小鼠模型中对NR2F2在肿瘤起始和进展过程中功能的全面分析
Comprehensive analysis of NR2F2 functions during tumor initiation and progression in a genetically engineered mouse model of high-grade serous ovarian carcinoma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
高级别浆液性卵巢癌(HGSOC)常在肿瘤已转移至腹膜腔的晚期才被确诊。我们知道HGSOC可起源于输卵管分泌上皮细胞,然而控制肿瘤自起源处发生转移的分子和细胞过程仍不清楚。利用基因工程小鼠模型(GEMM)和患者来源细胞系,我们旨在阐明HGSOC中肿瘤进展和转移的分子机制,重点关注孤儿核受体NR2F2——它被鉴定为具有成瘤能力的输卵管分泌上皮细胞亚群中一个潜在的转录调控因子。抑制NR2F2已在前列腺癌和乳腺癌的临床前模型中显示出治疗效果。更好地理解NR2F2在HGSOC中的功能,是开发靶向致癌性NR2F2治疗方法的关键一步。
方法:在卵巢肿瘤形成的不同时间点(2、4、6和8个月)从BPRN小鼠采集远端输卵管,采用单细胞RNA测序和深度学习AI工具(PHATE和MIOFlow)进行分析。随后利用bulk RNA测序评估表达靶向NR2F2的诱导型shRNA或乱序shRNA的小鼠和人卵巢癌细胞系的基因表达变化。进行免疫共沉淀和质谱(Co-IP/MS)分析,以鉴定在过表达NR2F2或经NR2F2小分子抑制剂处理的人卵巢癌细胞中与NR2F2相互作用的蛋白。采用染色质免疫沉淀测序(ChIP-seq)表征受NR2F2及其辅因子调控的基因和相关通路。
结果:单细胞RNA测序数据的轨迹分析发现,NR2F2及其靶基因富集于输卵管上皮细胞的一个亚群中。上调的NR2F2通路与肿瘤发生和转移基因特征相关。对诱导型NR2F2敲低的人和小鼠癌细胞系进行的bulk RNA测序表明,NR2F2调控参与细胞周期、细胞因子信号传导以及细胞外基质/整合素相互作用的信号通路。Co-IP/MS结果显示,NR2F2与多个肿瘤进展的关键调控因子相互作用,包括PARP1、beta-catenin和menin 1。ChIP-seq结果鉴定出受NR2F2及其辅因子直接调控的基因。
结论:通过在GEMM中对NR2F2功能的全面分析,我们鉴定出受NR2F2调控的基因和共转录因子。这些知识将增进我们对NR2F2在调控HGSOC起始及其自输卵管发生转移中作用的理解。我们的发现支持了评估NR2F2抑制剂在预防肿瘤细胞减灭术后转移复发方面治疗潜力的理论依据。
查看英文原文 English abstract
High-grade serous ovarian carcinoma (HGSOC) is often diagnosed at late stages when tumors have metastasized in the peritoneal cavity. We know HGSOC can originate from fallopian tube secretory epithelial cells, yet the molecular and cellular processes controlling tumor metastasis from the origin are still unclear. Using a genetically engineered mouse model (GEMM) and patient-derived cell lines, we aim to understand the molecular mechanism of tumor progression and metastasis in HGSOC with a focus on the orphan nuclear receptor NR2F2, which was identified as a potential transcriptional regulator in a subpopulation of fallopian tube secretory epithelial cells with tumor forming ability. Inhibition of NR2F2 has shown therapeutic effects in prostate and breast cancer preclinical models. A better understanding of NR2F2 functions in HGSOC is a critical step in developing therapeutic approaches to target oncogenic NR2F2.
Method: Distal oviducts collected from BPRN mice at different timepoints of ovarian tumor formation (2, 4, 6, and 8 months) were analyzed using single cell RNA-sequencing and deep learning AI tools (PHATE and MIOFlow). Bulk RNA sequencing was subsequently used to evaluate gene expression changes in murine and human ovarian cancer cell lines expressing inducible shRNA targeting NR2F2 or scramble shRNA. Co-immunoprecipitation and mass spectrometry (Co-IP/MS) were performed to identify NR2F2-interacting proteins in human ovarian cancer cells overexpressing NR2F2 or treated with a small molecule inhibitor of NR2F2. Chromatin immunoprecipitation sequencing (ChIP-seq) was used to characterize genes and related pathways regulated by NR2F2 and its co-factors.
Result: Trajectory analysis of single cell RNA-sequencing data identified that NR2F2 and its target genes are enriched in a subpopulation of oviduct epithelial cells. The upregulated NR2F2 pathway is associated with tumor development and gene signatures of metastasis. Bulk RNA sequencing of human and mouse cancer cell lines with inducible NR2F2 knockdown demonstrated that NR2F2 regulates signaling pathways involved in cell cycle, cytokine signaling, and extracellular matrix/integrin interactions. Co-IP/MS results show that NR2F2 interacts with several key regulators of tumor progression including PARP1, beta-catenin, and menin 1. ChIP-seq results identified genes directly regulated by NR2F2 and its co-factors.
Conclusion: Through comprehensive analyses of NR2F2 functions in the GEMM, we identified genes and co-transcriptional factors that are regulated by NR2F2. This knowledge will advance our understanding of NR2F2's role in regulating HGSOC initiation and metastasis from the fallopian tubes. Our findings support the rationale of evaluating the therapeutic potential of NR2F2 inhibitors in preventing metastatic recurrence after debulking surgery.
利益披露 Disclosure
M. Mansolf, None..
D. Liao, None..
S. G. Novo, None..
T. M. Hartwich, None..
J. Jathan, None..
K. Yang, None..
V. Kolesnyk, None.